https://allsci.com/news/biotech/vir-biotechnology-gilead-strikes-usd-90m-upfront/ AllScien 2026-10-14T18:11:43.048024Z Vir Biotechnology strikes USD 90m upfront deal with Gilead to build masked TCEs https://allsci.com/news/clinical-trials/biomea-fusion-bmf-650-fusions-shows-1532-weight/ AllScien 2026-10-14T17:33:16.926504Z Biomea reports early weight-loss signal for oral GLP-1 drug, seeks development partner https://allsci.com/news/biotech/kras-g12d-inhibitor-verastems-vs-7375-achieves-41/ AllScien 2026-10-14T17:12:31.200632Z Verastem’s KRAS G12D inhibitor shrinks pancreatic tumors in 41% of patients https://allsci.com/news/biotech/vs-7375-kras-g12d-verastem-raises-usd-250m-to/ AllScien 2026-10-14T16:43:21.497371Z Verastem raises USD 250m to advance VS-7375 KRAS G12D program https://allsci.com/news/clinical-trials/ulcerative-colitis-trial-first-patient-dosed-in/ AllScien 2026-10-14T16:28:28.079566Z GSK and Oxford Uni begin IL-18 antibody study to map treatment effects in ulcerative colitis https://allsci.com/news/biotech/eq504-trial-equillium-clears-australian/ AllScien 2026-10-14T16:16:15.189654Z Equillium clears Australian hurdle for first human trial of ulcerative colitis AhR modulator https://allsci.com/news/biotech/itr-251-clinical-trial-iteria-biopharma-registers/ AllScien 2026-10-14T15:10:30.146506Z Iteria plans first human trial of MAO-A inhibitor targeting advanced cancer https://allsci.com/news/biotech/alaunos-therapeutics-acquisition-acquires-velaris/ AllScien 2026-10-14T11:36:27.861932Z Alaunos pivots to PAH with Velaris acquisition and USD 350m financing https://allsci.com/news/clinical-trials/risankizumab-crohns-disease-abbvies-met-phase-iii/ AllScien 2026-10-14T11:12:06.124326Z AbbVie's subcutaneous risankizumab meets Phase III AFFIRM endpoints https://allsci.com/news/biotech/souffle-therapeutics-secures-oversubscribed-usd/ AllScien 2026-10-14T10:33:38.010651Z Soufflé rises with USD 135m Series B to advance FSHD and heart failure therapies https://allsci.com/news/biotech/hidradenitis-suppurativa-bispecific-antibody/ AllScien 2026-10-14T10:23:49.876177Z Shandong First Medical researchers identify IL-17A/IL-36 axis as therapeutic target in HS https://allsci.com/news/biotech/sec61-inhibitors-enodia-therapeutics-strikes/ AllScien 2026-10-13T17:41:35.147618Z Pfizer partners with Enodia on Sec61 protein degradation therapies in deal exceeding USD 500m https://allsci.com/news/biotech/alk7-obesity-therapy-roche-licenses-ronas-rnai-in/ AllScien 2026-10-13T17:37:20.346357Z Roche licenses Rona's ALK7 RNAi obesity therapy in deal worth up to USD 1.16b https://allsci.com/news/biotech/roginolisib-pi3k-nature-communications-papers/ AllScien 2026-10-13T17:33:08.983427Z Roginolisib studies detail PI3Kδ inhibition mechanism and Phase I survival data in uveal melanoma https://allsci.com/news/licensing-and-partnerships/neurotrophic-keratitis-visara-licenses-nerve/ AllScien 2026-10-13T17:30:06.821288Z NovaBridge's Visara expands ophthalmology pipeline with USD 111m Hiteck licensing deal https://allsci.com/news/biotech/sirna-delivery-undecimal-bio-raises-usd-18m-seed/ AllScien 2026-10-13T17:25:53.127275Z Undecimal Bio raises USD 18m seed round to extend siRNA delivery beyond the liver https://allsci.com/news/clinical-trials/biontech-bnt113-biontechs-misses-phase-iii/ AllScien 2026-10-13T17:18:51.730642Z BioNTech's BNT113 misses Phase III PFS endpoint in head and neck cancer, OS analysis continues https://allsci.com/news/biotech/melflufen-glioblastoma-oncopeptides-shows-signs/ AllScien 2026-10-13T17:07:06.660405Z Oncopeptides' melflufen shows signs of blood-brain barrier penetration in early INSULA glioblastoma data https://allsci.com/news/clinical-trials/remigromig-dme-meets-non-inferiority-primary/ AllScien 2026-10-13T17:01:21.810553Z Merck's remigromig meets Phase III DME endpoint, but retinopathy safety signal emerges https://allsci.com/news/grants/protein-misfolding-arpa-h-backs-georgetown-and/ AllScien 2026-10-13T15:49:53.962961Z ARPA-H commits up to USD 152m to protein misfolding research across six consortia https://allsci.com/news/research/preinvasive-lung-cancer-ucl-identifies-immune/ AllScien 2026-10-13T15:21:39.714935Z UCL research identifies preinvasive immune circuit linked to lung cancer development https://allsci.com/news/clinical-trials/brd9-degrader-amphista-therapeutics-doses-first/ AllScien 2026-10-13T15:10:28.742136Z Amphista doses first patient in Phase I BRD9 degrader trial for AML https://allsci.com/news/precision-therapeutics-usd-25m-smilow-foundation/ AllScien 2026-10-13T15:01:11.743476Z Penn Medicine receives USD 25m gift to establish cardiovascular precision therapeutics center https://allsci.com/news/grants/calciphylaxis-trial-massachusetts-general/ AllScien 2026-10-13T13:56:48.454848Z Mass General picks up USD 2.46m FDA grant for Phase II calciphylaxis trial https://allsci.com/news/clinical-trials/efzimfotase-alfa-astrazenecas-misses-phase-iii/ AllScien 2026-10-13T13:25:16.559050Z AstraZeneca details Phase III HICKORY endpoint miss for efzimfotase alfa in hypophosphatasia https://allsci.com/news/grants/ultra-rare-sarcomas-sloan-kettering-receives-15m/ AllScien 2026-10-13T13:08:32.522353Z FDA awards Sloan-Kettering USD 1.5m for rare sarcoma drug target discovery https://allsci.com/news/clinical-trials/axatilimab-pulmonary-fibrosis-maxpire-failure/ AllScien 2026-10-13T12:58:50.320311Z MAXPIRe failure ends Syndax's axatilimab program in idiopathic pulmonary fibrosis https://allsci.com/news/licensing-and-partnerships/micurx-adc-license-plans-to-out-license/ AllScien 2026-10-13T11:13:39.470990Z MicuRx plans ADC licensing deal with ClearideBio worth up to USD 974 million in disclosed payments https://allsci.com/news/clinical-trials/livmarli-cholestatic-pruritus-cuts-in-phase-iii/ AllScien 2026-10-13T11:04:04.896291Z Mirum's Livmarli meets Phase III endpoint in ultra-rare cholestatic liver diseases https://allsci.com/news/clinical-trials/celiac-disease-trial-anb033-meets-key-histologic/ AllScien 2026-10-13T10:12:11.663872Z First Tracks' ANB033 meets histologic endpoints in Phase Ib celiac disease trial https://allsci.com/news/clinical-trials/ryz101-action-1-trial-meets-primary-pfs-endpoint/ AllScien 2026-10-13T08:42:34.733503Z BMS' RYZ101 meets Phase III endpoint in landmark alpha-radiopharmaceutical trial https://allsci.com/news/clinical-trials/admilparant-ipf-phase-iii-aloft-ipf-trial-of/ AllScien 2026-10-12T20:13:32.064551Z BMS' admilparant meets Phase III IPF endpoint at lower dose, misses at higher dose https://allsci.com/news/clinical-trials/obuprazine-schizophrenia-hits-primary-endpoint/ AllScien 2026-10-12T18:57:48.542156Z Tortugas boosted by positive China Phase II data for obuprazine in schizophrenia